Protalix BioTherapeutics (PLX) Reports Q4 EPS of $0.02
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- Wall St futures rise as AI stocks catch their breath; midterms in focus
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops more than 4% on talks aimed at ending US-Iran war
- Why has the market become so unforgiving of AI earnings?
- EchoStar rises on report SpaceX in talks to buy Boost Mobile or tap its network
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $2.59 --0%
EPS Growth %: -266.7%
Financial Fact:
REVENUES: 4.67M
Today's EPS Names:
LTBR, AES, SYRS, More
EPS Growth %: -266.7%
Financial Fact:
REVENUES: 4.67M
Today's EPS Names:
LTBR, AES, SYRS, More
Join SI Premium – FREE
Protalix BioTherapeutics (NYSE: PLX) reported Q4 EPS of $0.02, versus ($0.04) reported last year. Revenue for the quarter came in at $3.8 million, versus $1.8 million reported last year.
For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Public Service Enterprise (PEG) Misses Q3 EPS by 4c ; Offers Guidance
- Seaport Therapeutics, Inc. (SPTX) Misses Q3 EPS by 49c
- NAPCO Security Tech (NSSC) Misses Q1 EPS by 4c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
